Phyllis Gardner

Phyllis I.
Gardner is the founder of Genomics Collaborative, Inc. Former positions include Director at Pharmacyclics LLC, Director at BioMarin Pharmaceutical, Inc., Director at Aerogen, Inc., Director at Ventaira Pharmaceuticals, Inc., Independent Director at CohBar, Inc. from 2019 to 2022, Director at Draupnir LLC, Independent Non-Executive Director at Corium LLC (Massachusetts) from 2007 to 2018, Independent Director at Parnell Pharmaceuticals Holdings Ltd. from 2014 to 2015, Director-Fellows Board at Harvard Medical School from 2013 to 2025, Non-Executive Director at Firebrick Pharma Ltd. from 2020 to 2025, Director at Aronex Pty Ltd., Independent Director at Revance Therapeutics, Inc. from 2014 to 2021, Independent Director at MiMedx Group, Inc. from 2021 to 2024, Vice President-Research & Principal Scientist at ALZA Corp.
from 1994 to 1998, Adjunct Partner at Essex Woodlands Management, Inc. from 1999 to 2009, Professor at Stanford University from 1984 to 2025, and Advisors at Avestria Ventures Management LLC.
Education includes an undergraduate degree from the University of Illinois and a doctorate from Harvard Medical School.